Cyclophosphamide therapy in pediatric multiple sclerosis

The Hospital for Sick Children, University of Toronto, Canada.
Neurology (Impact Factor: 8.29). 06/2009; 72(24):2076-82. DOI: 10.1212/WNL.0b013e3181a8164c
Source: PubMed


To review our multicenter experience with cyclophosphamide in the treatment of children with multiple sclerosis (MS).
Retrospective chart review of children with MS treated with cyclophosphamide. Demographic, clinical, treatment, and MRI parameters were collected.
We identified 17 children with MS treated with cyclophosphamide. All but one had worsening of Expanded Disability Status Scale scores or multiple relapses prior to treatment initiation. Children were treated with one of three regimens: 1) induction therapy alone; 2) induction therapy with pulse maintenance therapy; or 3) pulse maintenance therapy alone. Treatment resulted in a reduction in relapse rate and stabilization of disability scores assessed 1 year after treatment initiation in the majority of patients. Longer follow-up was available for most cases. Cyclophosphamide was well tolerated in most patients. However, side effects included vomiting, transient alopecia, osteoporosis, and amenorrhea. One patient developed bladder carcinoma that was successfully treated.
Cyclophosphamide is an option for the treatment of children with aggressive multiple sclerosis refractory to first-line therapies. Recommendations regarding patient selection, treatment administration, and monitoring are discussed.

Full-text preview

Available from:
  • Source
    • "g) in the treatment of 17 children with MS. The side effects observed were vomiting, transient alopecia, osteoporosis, amenorrhea, and a bladder carcinoma in one patient [71]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cyclophosphamide (cy) is an alkylating agent used to treat malignancies and immune-mediated inflammatory nonmalignant processes. It has been used as a treatment in cases of worsening multiple sclerosis (MS). Cy is currently used for patients whose disease is not controlled by beta-interferon or glatiramer acetate as well as those with rapidly worsening MS. The most commonly used regimens involve outpatient IV pulse therapy given with or without corticosteroids every 4 to 8 weeks. Side effects include nausea, headache, alopecia, pain, male and women infertility, bladder toxicity, and risk of malignancy. Previous studies suggest that cy is effective in patients in the earlier stages of disease, where inflammation predominates over degenerative processes. Given that early inflammatory events appear to correlate with later disability, a major question is whether strong anti-inflammatory drugs, such as cy, will have an impact on later degenerative changes if given early in the disease to halt inflammation.
    03/2011; 2011(1):961702. DOI:10.4061/2011/961702
  • Source
    • "Its effects on MRI lesions remains undefined. Infections (especially with white blood cells < 1500/mm3), nausea, transient alopecia, gonad failure, hemorrhagic cystitis, bladder and blood cancers (particularly if cumulative cyclophosphamide dosage is 100 g or more [44]), could derive from treatment with cyclophosphamide [9, 11, 44]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammatory demyelinating diseases comprise a spectrum of disorders affecting the myelin of the central and peripheral nervous system. These diseases can usually be differentiated on the basis of clinical, radiological, laboratory and pathological findings. Recent studies have contributed to current awareness that inflammatory demyelinating diseases are not restricted to the adult age group, but are more common in pediatric age than previously believed. Some of pediatric inflammatory demyelinating diseases carry an unfavorable long-term prognosis but appropriate treatments can improve the outcome. The possibility of physical and cognitive disability resulting from these diseases, highlights the urgent need for therapeutic strategies for neurorehabilitation, neuroregeneration, and neurorepair. This review discusses characteristics of primary demyelinating diseases more frequently observed in childhood, focusing on epidemiology, clinical aspects and treatments.
    DNA research: an international journal for rapid publication of reports on genes and genomes 06/2010; 8(2):135-48. DOI:10.2174/157015910791233141 · 3.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper briefly describes the advantages of Single Sideband for the Citizens Radio Service, and converts the needs of this service to a working set of specifications for an SSB transceiver. Performance, reliability and economic considerations were the paramount objectives. Design techniques of the resulting low cost solid state transceiver are discussed. These include design features and performance of the bilateral modulator-detector, diode switching, squelch, noise silencer, and transmitter circuitry. A discussion of the resulting field performance of the SSB transceiver versus its AM counterparts is also presented.
    Vehicular Technology Conference, 1966. 17th IEEE; 01/1967
Show more